Table 2: Summary of Aptamer-MB pull down experiments using mass spectrometry detection.
Trial 1: Buffer + 100 µl of Aptamer-MBs | ||||
Target | AA-3 | AA-3 | GHRP-6 | GHRP-6 |
Aptamer | AS-28F | AU-23F | G6S-16F | G6U-18R |
Detection | + | + | - | low + |
Trial 2: Buffer + 500 µl of Aptamer-MBs | ||||
Target | AA-3 | AA-3 | GHRP-6 | GHRP-6 |
Aptamer | AS-28F | AU-23F | G6S-16F | G6U-18R |
Detection | + | + | + | - |
Trial 3: Serum + 500 µl of Aptamer-MBs | ||||
Target | AA-3 | AA-3 | GHRP-6 | GHRP-6 |
Aptamer | AAS-28F | AAU-23F | G6S-16F | G6U-18R |
Detection | + | + | + | - |
Trial 4: Urine + 500 µl of Aptamer-MBs | ||||
Target | AA-3 | AA-3 | GHRP-6 | GHRP-6 |
Aptamer | AAS-28F | AAU-23F | G6S-16F | G6U-18R |
Detection | + | + | + | + |
Notes: (+): Successful detection of the subject peptide by MS at any level; (-): No target peptide detection by MS and (+ low): Barely perceptible peak for the subject peptide. Negative control results employing streptavidin (SAv)-MBs without aptamers are not shown in the table, but were negative (i.e., failed to show any evidence of AA-3 or GHRP-6 adhering to SAv-MBs by MS when buffer was spiked with 100 µg of AA-3 or GHRP-6 and the pull down assay was conducted without biotinylated aptamers on the SAv-MBs).